Clinical Trial

Atacicept in Multiple Glomerular Diseases

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
Protocol Amendment History 1 change
notable Enrollment increased: 200 -> 250 participants 2026-06-27
Trial Details
NCT Number NCT06983028
Lead Sponsor Vera Therapeutics, Inc.
Conditions pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Enrollment 250 participants
Start Date 2025-07-07
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-26